发明名称 |
NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES |
摘要 |
<p>The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction ("GEJ"), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction ("GEJ"). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction ("GEJ").</p> |
申请公布号 |
WO2012020123(A9) |
申请公布日期 |
2012.06.07 |
申请号 |
WO2011EP63932 |
申请日期 |
2011.08.12 |
申请人 |
F. HOFFMANN-LA ROCHE AG;DELMAR, PAUL;FOERNZLER, DOROTHEE;SCHERER, STEFAN |
发明人 |
DELMAR, PAUL;FOERNZLER, DOROTHEE;SCHERER, STEFAN |
分类号 |
A61K45/06;A61K31/505;A61K31/7068;A61K33/24;A61K39/395;A61P35/00;G01N33/68 |
主分类号 |
A61K45/06 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|